Development asset linked to CytoMed Therapeutics in public FDA and regional records.
pharma · Colorectal Cancer · Cancer · GDTC
CytoMed Therapeutics
CytoMed Therapeutics Ltd
CytoMed Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 COMMONWEALTH LANE, U0, SG HQ
2018 Founded
26 Employees
Public company Type
GDTC · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1 COMMONWEALTH LANE, U0, SG
- Founded
- 2018
- Employees
- 26
- Programs
- 4
- Drugs
- 12
- Patents
- 3
CytoMed Therapeutics pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CytoMed Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in CytoMed Therapeutics's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in CytoMed Therapeutics's portfolio.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.
-
Development asset linked to CytoMed Therapeutics in public FDA and regional records.